Head of Business Development
Kassim Kolia, Head of Business Development, joined in 2012 and is responsible for Business Development, Sales and Marketing and Gene Therapy Market Intelligence within FinVector. He has over 15 years in product development and cGMP manufacturing. Kassim joined FinVector from Eden Biodesign Limited, part of Watson Pharmaceuticals, Inc., (now Actavis) where, since 2006, he has been responsible for the business development of Eden Biodesign's contract development and manufacturing services and under Watson responsible for Business Development activities on Biosimilar’s and Biologic technologies. Before joining Eden Biodesign, Kassim was Key Account Manager at Bachem (UK) Ltd where he was responsible for business development of cGMP business opportunities for the company in the UK and Ireland. Prior to that, Kassim has extensive hands on cGMP manufacturing experience having held roles of cGMP Line Manager at Lonza Biologics and Team Leader at Evotec.